Fate Therapeutics (FATE) stock surges 86.4% YTD on positive pipeline progress

From Nasdaq: 2024-04-06 02:17:00

Fate Therapeutics (FATE) shares have surged 86.4% this year due to positive sentiment around its innovative pipeline and recent progress. The company uses cell programming to create better cell therapies by engineering human induced pluripotent stem cells. FATE is conducting multiple clinical trials and collaborating with pharmaceutical companies on potential therapies. The company recently raised $100 million to fund clinical trials and other purposes. Additionally, FATE reported better-than-expected fourth-quarter results with decreased research and development expenses. However, the termination of a collaboration agreement affected collaboration revenues. The manufacturing and distribution of cell product candidates pose risks. FATE currently carries a Zacks Rank #3 (Hold).

Meanwhile, a massive infrastructure push in the United States is expected to create opportunities for certain stocks. This bipartisan initiative will involve trillions of dollars being spent, leading to potential fortunes for companies involved in construction, repair, cargo hauling, and energy transformation. Zacks has released a Special Report highlighting 5 special companies poised to benefit the most from this infrastructure spending. Investors can download the report for free to discover potential opportunities to capitalize on this trend.



Read more at Nasdaq: Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress